Par Gets Approval for Depression Drug

Par Pharmaceutical Co.’s wholly-owned subsidiary, Kali Laboratories, Inc., received final approval from the FDA for its aNDA for tranylcypromine sulfate tablets, 10 mg. Tranylcypromine is the generic version of GlaxoSmithKline’s Parnate and is used for the treatment of depression. Annual U.S. sales of Parnate exceed $6 million. Par will begin shipping the product immediately.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters